Patents by Inventor Ulrich Brinkmann

Ulrich Brinkmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210122832
    Abstract: Herein is reported a multispecific antibody comprising two circular fusion polypeptides each of them comprising a VH/VL-pair and thereby a first and a second binding site, whereby a third VH/VL-pair and thereby a third binding site is formed by the associated of the two circular fusion polypeptides.
    Type: Application
    Filed: April 29, 2020
    Publication date: April 29, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Steffen Dickopf, Guy Georges, Irmgard Thorey
  • Publication number: 20210116455
    Abstract: The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T) cell assays to test novel target antigen binding moieties in different formats. Furthermore, the present invention relates to the use of reporter CAR-T cells, transfected/transduced with an engineered CAR capable of specific binding to a recognition domain comprising a tag.
    Type: Application
    Filed: August 31, 2020
    Publication date: April 22, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Diana DAROWSKI, Steffen DICKOPF, Christian JOST, Christian KLEIN
  • Publication number: 20210069338
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Application
    Filed: May 13, 2020
    Publication date: March 11, 2021
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Publication number: 20210061867
    Abstract: Herein is reported a composition for the targeted delivery of large nucleic acids to the nucleus of a eukaryotic cell comprising non-covalent complexes of histones in form of assembled nucleosomes, a large nucleic acid, a hapten, and a bispecific binder that has a first binding specificity to the hapten and a second binding specificity to a cell-surface target present on the eukaryotic cell, wherein the histone and/or the nucleic acid is/are covalently bound/conjugated to the hapten, the histone and the large nucleic acid are associated (non-covalently) with each other/form a non-covalent complex, and the hapten and the bispecific binder are associated with each other/bound to each other by the first binding specificity of the bispecific binder.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 4, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Tobias Killian
  • Publication number: 20210047394
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Publication number: 20210024648
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Application
    Filed: February 10, 2020
    Publication date: January 28, 2021
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellne, Sabine Imhof-Jung, Ulrich Brinkmann, Guy Georges
  • Publication number: 20200392253
    Abstract: Herein is reported a method for the generation of multispecific antibodies by a half-antibody exchange reaction between two 2/3-IgGs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assemble full length bispecific antibodies. The method can be performed in the absence of reducing agents and does not require hinge region disulfide bonds in the starting 2/3-IgGs.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Stefan Dengl, Guy Georges, Eike Hoffmann, Klaus Mayer, Felix Bormann
  • Publication number: 20200392254
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: March 17, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Wolfgang SCHAEFER, Klaus MAYER
  • Patent number: 10806795
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 20, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Publication number: 20200262904
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: August 20, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Publication number: 20200255522
    Abstract: Herein is reported a method for the generation of multispecific antibodies directly on the cell-surface at the site of action by a half-antibody exchange reaction between two 2/3-IgGs or two 2/3-BiFabs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assembled full length bi- or multi-specific antibodies. The method is performed in the absence hinge region disulfide bonds in the starting 2/3-IgGs or 2/3-BiFabs.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 13, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Klaus Mayer, Steffen Dickopf
  • Publication number: 20200181280
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Application
    Filed: June 3, 2019
    Publication date: June 11, 2020
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
  • Publication number: 20200164064
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Application
    Filed: October 29, 2019
    Publication date: May 28, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Ulrich BRINKMANN, Stefan DENGL, Sebastian DZIADEK, Guy GEORGES, Michael GROTE, Alexander HAAS, Eike HOFFMANN
  • Patent number: 10633457
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Wolfgang Schaefer, Klaus Mayer
  • Publication number: 20200062826
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: May 15, 2019
    Publication date: February 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Rebecca CROASDALE, Eike HOFFMANN, Christian KLEIN, Ekkehard MOESSNER, Juergen Michael SCHANZER, Claudio SUSTMANN, Pablo UMANA
  • Patent number: 10561737
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: February 18, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Publication number: 20200002437
    Abstract: The invention provides anti-BRDU antibodies and methods of using the same.
    Type: Application
    Filed: March 5, 2019
    Publication date: January 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Johannes Auer, Wilma Lau
  • Publication number: 20200000929
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 2, 2020
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Patent number: 10519249
    Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 31, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Eike Hoffmann, Stefan Dengl, Klaus Mayer
  • Patent number: 10517945
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 31, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Joerg Benz, Ulrich Brinkmann, Stefan Dengl, Sebastian Dziadek, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann